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A human immunodeficiency virus type 2 (HIV-2)–infected
woman experienced asymptomatic superinfection with HIV-
1 subtype AG. She did not have cross-neutralizing autologous
HIV-1 antibodies before and shortly after HIV-1 superinfec-
tion. This evidence supports a mechanism other than cross-
neutralizing antibodies for the mild course of HIV-1 infec-
tion in this woman.
Interclade and intraclade superinfection with human immu-
nodeficiency virus type 1 (HIV-1) strains has been well doc-
umented during recent years. Incidence rates are estimated to
reach 3%–8% per year (with higher levels during primary in-
fection than during chronic infection), rendering superinfec-
tion a major challenge for HIV drug and vaccine design [1–
11]. In contrast, HIV-1 and HIV-2 coinfection is observed rel-
atively infrequently in regions where both strains cocirculate at
high levels [11–13]. A prospective epidemiological study from
Senegal suggested that HIV-2–infected individuals may be pro-
tected partially from HIV-1 infection [14, 15], although other
studies in West Africa could not confirm these findings [16,
17]. In addition, a variety of in vitro studies have proposed
potential protective mechanisms [14, 18–20]. A caveat of pre-
vious studies remains: HIV-1 and HIV-2 dual infections could
rarely be attributed clearly to either coinfection or superinfec-
tion, because sequential sampling to prove superinfection was
missing in most cases. Here, we describe an HIV-2–infected
woman who was unambiguously superinfected with HIV-1.
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Case report. In December 2001, a 39-year-old pregnant
woman from Benin presented to our hospital with preterm
contractions. The results of an HIV-1/2/O screening test were
reactive. Western blot analysis revealed a positive result for HIV-
2 but a negative result for HIV-1. Plasma HIV-1 RNA was
undetectable at that time (Roche Monitor HIV-1 assay, version
1.5; detection limit, 50 copies/mL). HIV-2 infection had already
been diagnosed in December 1999 (figure 1). The infant was
born by cesarean delivery in the absence of antiretroviral treat-
ment in December 2001 and remained free of HIV infection.
To monitor for HIV-2 viremia, a product-enhanced reverse
transcriptase assay [21] was performed in January 2002. Reverse
transcriptase activity of 1266 nU/mL was detected (HIV RNA
level, ∼24,000 copies/mL) [21] and was thought to be attrib-
utable to HIV-2, because the plasma HIV-1 RNA test results
were previously negative. The baseline CD4 cell count at that
time was 729 cells/mL (CD4 percentage, 48%). In May 2002,
the CD4 cell count decreased suddenly to 340 cells/mL (CD4
percentage, 26%). Subsequently, the CD4 cell count increased
to 578 cells/mL (CD4 percentage, 27%) and remained stable
(440–600 cells/mL) for the next 5 years. In November 2005, a
plasma HIV-1 RNA test was performed, the results of which
demonstrated measurable viral RNA. The assay was repeated,
and the results confirmed the reactivity. This result raised the
questions of whether this was a rare case of HIV-2 infection
that was detectable by the Roche assay [22], whether the initial
serological diagnosis of HIV-2 infection had been incorrect, or
whether the patient had HIV-1 and HIV-2 coinfection.
Sequencing of the amplicon and phylogenetic analysis re-
vealed an HIV-1 sequence related to clade A. Thus, a retro-
spective analysis of stored samples was started. Western blot
analysis from May 2002 revealed that, in addition to the pre-
vious HIV-2 infection, HIV-1 infection had been newly ac-
quired (figure 1); in addition, plasma HIV-1 RNA was detect-
able at the low level of 540 copies/mL. A plasma sample from
January 2002, a time point at which the HIV-1 Western blot
result was still negative, was also tested for HIV-1 RNA, and a
viral load of 722 copies/mL was detected. Thus, asymptomatic
primary HIV-1 infection occurred in January 2002. Subse-
quently, the HIV-1 RNA level increased to 1760 copies/mL in
October 2002, spontaneously decreased to 63 copies/mL in Jan-
uary 2005, and then oscillated between 60 and 660 copies/mL
during the entire follow-up period (until the end of July 2008).
No HIV-associated disease developed during the entire obser-
vation period of 6 years, and it was not necessary to start
antiretroviral treatment. HIV-1 proviral DNA amplifications for
e118 • CID 2009:48 (1 June) • BRIEF REPORT
Figure 2. Line immunoassay with specimens obtained before and after
human immunodeficiency virus type 1 (HIV-1) seroconversion. All speci-
mens were tested retrospectively in parallel with strips of the same lot.
Positions of HIV-1– or HIV-2–specific envelope antibodies are shown in
bold. The specimen obtained on day 0 (in January 2002) showed sero-
positivity only for HIV-2. Seroconversion to HIV-1 is evident by the in-
duction of HIV-1–specific envelope antibodies and by an increase of the
reactivity to matrix protein p17 and endonuclease p31 in the specimen
from day 127. NEG, seronegative reaction control.
Figure 1. Synopsis of the time of events. Day 0 is defined as the day when diagnosis of human immunodeficiency virus type 1 (HIV-1) superinfection
was made (in January 2002). The logarithmic scale delineates the longitudinal plasma HIV-1 load (squares) and neutralizing antibody titers of 70%
(NT70%) and 90% (NT90%). The horizontal dotted line represents the cutoff value (!40 copies/mL) for nondetectability of any neutralizing activity
against the autologous virus isolate. CD4 cell counts are represented by triangles. In addition, sequential Western blot (WB) results for HIV-2 and
HIV-1, by the time of HIV-1 virus isolation from plasma samples, are shown to mark their overall temporal relationship.
gag and pol genes were positive. Phylogenetic analysis of the
entire gag p24 sequence revealed recombinant virus CRF02_AG.
The results of several plasma HIV-2 RNA tests remained neg-
ative, whereas HIV-2 proviral DNA was undetectable by stan-
dard polymerase chain reaction (PCR) but was detected un-
ambiguously by a high DNA input nested DNA PCR [23].
Phylogenetic analysis of the sequenced amplicon revealed HIV-
2 subtype B.
A replication-competent isolate of the superinfecting strain
was isolated after 1580 days of follow-up. Of note, no HIV-1–
neutralizing activity was detectable in the patient’s plasma sam-
ples before HIV-1 superinfection (figure 1). Thus, HIV-2 lacked
the ability to induce a protective, cross-neutralizing activity
against HIV-1. A significant anti–HIV-1–neutralizing activity
evolved after several months of HIV-1 infection, consistent with
previous reports [24, 25].
Assays used. For HIV-1 and HIV-2 antibodies, the follow-
ing assays were used: HIV-1/2/O enzyme-linked immunosor-
bent assay (for screening), Western blot analysis (Genelabs Di-
agnostics), and line immunoassay (INNO-LIA HIV I/II Score;
Innogenetics). For HIV-1 RNA, the Cobas Amplicor HIV-1
Monitor assay, version 1.5, was used. Retrospective analyses of
HIV-1 RNA in plasma samples or proviral DNA in peripheral
blood mononuclear cells (PBMCs) used in-house real-time
PCR with primers in gag and pol. For HIV-2 RNA or DNA
PCR, PCR with primers in the gag leader sequence was used
[26]. To measure reverse transcriptase activity, an ultrasensitive
particle-enhanced reverse transcriptase assay was used [21].
The superinfecting autologous HIV-1 isolate was isolated
from CD4 cells obtained after 1580 days of follow-up, and the
autologous plasma neutralization activity was measured in a
PBMC-based neutralization assay as described elsewhere [27]
.
Discussion. We report an unambiguous case of superin-
fection with HIV-1 CRF02_AG in an HIV-2–infected woman.
Although the initial HIV-1 load was low (722 copies/mL) and
peaked at only 1760 copies/mL, the sudden decrease in the
CD4 cell count in this patient is consistent with primary HIV-
1 infection and suggests that the superinfection occurred from
December 2001 through January 2002, when results of the HIV-
1 RNA assay were first positive but the results of INNO-LIA
were negative for HIV-1–specific envelope antibodies (figure
2). HIV-1 and HIV-2 coinfection could clearly be ruled out by
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identification of an HIV-2–positive Western blot result for this
patient in December 1999. Of note, the patient did not ex-
perience any symptoms or signs of an acute retroviral syn-
drome. During the following 6 years, the HIV-1 load sponta-
neously decreased and oscillated at low levels (60–660 copies/
mL), and the CD4 cell count fluctuated between 440 and 600
cells/mL (CD4 percentage, 23%–30%). It has to be considered
that the infecting HIV-1 strain, as most isolates of CRF02_AG,
contained a critical mismatch in 1 of the HIV-1 monitor primer
binding sites [28]; thus, the viral load may have been under-
estimated. Despite repeated attempts, HIV-2 RNA remained
undetectable in plasma, but persistence of HIV-2 infection
could be documented by measuring HIV-2 proviral DNA levels
in PBMCs with use of a supersensitive high-input procedure
[23]. This case illustrates that, in an HIV-2–infected patient
who encounters a sudden decrease in CD4 cell count, potential
HIV-1 superinfection needs to be verified.
Previous studies have suggested that HIV-2 infection may
partially protect patients from subsequent HIV-1 infection but
not vice versa [15, 29]. Whether this is indeed the case is still
under debate. Several clinical and basic research studies chal-
lenged these observations [16, 17], whereas other in vitro in-
vestigations located potential mechanisms by which HIV-2 in-
fection could restrict or protect patients from HIV-1 infection,
including CCR5 downregulation by HIV-2 [14], cross-reactive
anti–HIV-1 antibody induced by HIV-2 [20], higher b-che-
mokine levels in HIV-2–infected patients [19], and viral inter-
ference at the transcriptional level [18]. To test the hypothesis
that, in our patient, potentially cross-reactive anti–HIV-1 an-
tibodies might have been induced by the previous HIV-2 in-
fection, we longitudinally assessed neutralizing activity of the
patient plasma against the autologous HIV-1 virus isolate. Of
note, before and shortly after superinfection, no anti–HIV-1
plasma–neutralizing activity was detectable (figure 1). However,
optimal antibody response could not be tested, because a viral
isolate from the time of primary HIV-1 infection was not
available.
In conclusion, our case is particular in several ways. First, it
is a rare case of an unambiguously documented HIV-2 and
HIV-1 superinfection. Second, the patient had asymptomatic
acute HIV-1 infection with a low viral load, and subsequently,
HIV-1 RNA levels remained low in the absence of any treatment
for 6 years. HIV-1 superinfection only transiently led to a de-
crease in CD4 cell count, and for the entire follow-up period,
no disease progression occurred; altogether, the course of the
infection resembles chronic HIV-2 infection rather than HIV-
1 infection. We could not detect cross-neutralizing antibodies
against HIV-1 induced by HIV-2. Thus, mechanisms other than
neutralizing antibody response were most likely responsible for
this benign course of disease.
Acknowledgments
We thank the patient, for participating in this study, and Joseph Wong,
for helpful discussions and for reading the manuscript.
Financial support. Swiss National Science Foundation (320000–
116035 to H.F.G.).
Potential conflicts of interest. All authors: no conflicts.
References
1. Casado C, Pernas M, Alvaro T, et al. Coinfection and superinfection
in patients with long-term, nonprogressive HIV-1 disease. J Infect Dis
2007; 196:895–9.
2. Chohan B, Lavreys L, Rainwater SM, Overbaugh J. Evidence for fre-
quent reinfection with human immunodeficiency virus type 1 of a
different subtype. J Virol 2005; 79:10701–8.
3. Jost S, Bernard MC, Kaiser L, et al. A patient with HIV-1 superinfection.
N Engl J Med 2002; 347:731–6.
4. Koelsch KK, Smith DM, Little SJ, et al. Clade B HIV-1 superinfection
with wild-type virus after primary infection with drug-resistant clade
B virus. AIDS 2003; 17:F11–6.
5. Pernas M, Casado C, Fuentes R, Perez-Elias MJ, Lopez-Galindez C. A
dual superinfection and recombination within HIV-1 subtype B 12
years after primoinfection. J Acquir Immune Defic Syndr 2006; 42:
12–8.
6. Piantadosi A, Chohan B, Chohan V, McClelland RS, Overbaugh J.
Chronic HIV-1 infection frequently fails to protect against superin-
fection. PLoS Pathog 2007; 3:e177.
7. Smith DM, Wong JK, Hightower GK, et al. Incidence of HIV super-
infection following primary infection. JAMA 2004; 292:1177–8.
8. Smith DM, Wong JK, Hightower GK, et al. HIV drug resistance ac-
quired through superinfection. AIDS 2005; 19:1251–6.
9. van der Kuyl AC, Kozaczynska K, van den Burg R, et al. Triple HIV-
1 infection. N Engl J Med 2005; 352:2557–9.
10. Yerly S, Jost S, Monnat M, et al. HIV-1 co/super-infection in intra-
venous drug users. AIDS 2004; 18:1413–21.
11. McCutchan FE, Hoelscher M, Tovanabutra S, et al. In-depth analysis
of a heterosexually acquired human immunodeficiency virus type 1
superinfection: evolution, temporal fluctuation, and intercompartment
dynamics from the seronegative window period through 30 months
postinfection. J Virol 2005; 79:11693–704.
12. Sarr AD, Hamel DJ, Thior I, et al. HIV-1 and HIV-2 dual infection:
lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts.
AIDS 1998; 12:131–7.
13. Sarr AD, Sankale JL, Gueye-Ndiaye A, Essex M, Mboup S, Kanki PJ.
Genetic analysis of HIV type 2 in monotypic and dual HIV infections.
AIDS Res Hum Retroviruses 2000; 16:295–8.
14. Shea A, Sarr DA, Jones N, et al. CCR5 receptor expression is down-
regulated in HIV type 2 infection: implication for viral control and
protection. AIDS Res Hum Retroviruses 2004; 20:630–5.
15. Travers K, Mboup S, Marlink R, et al. Natural protection against HIV-
1 infection provided by HIV-2. Science 1995; 268:1612–5.
16. Schim van der Loeff MF, Aaby P, Aryioshi K, et al. HIV-2 does not
protect against HIV-1 infection in a rural community in Guinea-Bissau.
AIDS 2001; 15:2303–10.
17. Greenberg AE. Possible protective effect of HIV-2 against incident HIV-
1 infection: review of available epidemiological and in vitro data. AIDS
2001; 15:2319–21.
18. Browning CM, Cagnon L, Good PD, Rossi J, Engelke DR, Markovitz
DM. Potent inhibition of human immunodeficiency virus type 1 (HIV-
1) gene expression and virus production by an HIV-2 tat activation-
response RNA decoy. J Virol 1999; 73:5191–5.
19. Kokkotou EG, Sankale JL, Mani I, et al. In vitro correlates of HIV-2-
mediated HIV-1 protection. Proc Natl Acad Sci U S A 2000; 97:
6797–802.
20. Weiss RA, Clapham PR, Weber JN, et al. HIV-2 antisera cross-neutralize
HIV-1. AIDS 1988; 2:95–100.
e120 • CID 2009:48 (1 June) • BRIEF REPORT
21. Boni J, Pyra H, Schupbach J. Sensitive detection and quantification of
particle-associated reverse transcriptase in plasma of HIV-1-infected
individuals by the product-enhanced reverse transcriptase (PERT) as-
say. J Med Virol 1996; 49:23–8.
22. Schutten M, Ende ME, Niesters HG, Osterhaus A. Cross-reactivity of
the Cobas Amplicor HIV-1 Monitor version 1.5 quantitative plasma
HIV-1 RNA assay with HIV-2 [abstract 959]. In: Program and abstracts
of the 11th Conference on Retroviruses and Opportunistic Infections
(San Francisco). 2004.
23. Boni J, Shah C, Flepp M, Luthy R, Schupbach J. Detection of low copy
numbers of HIV-1 proviral DNA in patient PBMCs by a high-input,
sequence-capture PCR (Mega-PCR). J Med Virol 2004; 72:1–9.
24. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of
the neutralizing antibody response to HIV type 1 infection. Proc Natl
Acad Sci U S A 2003; 100:4144–9.
25. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape
by HIV-1. Nature 2003; 422:307–12.
26. Damond F, Benard A, Ruelle J, et al. Quality control assessment of
HIV-2 viral load quantification assays: results from an international
collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008; 46:
2088–91.
27. Trkola A, Kuster H, Leemann C, et al. Humoral immunity to HIV-1:
kinetics of antibody responses in chronic infection reflects capacity of
immune system to improve viral set point. Blood 2004; 104:1784–92.
28. Swanson P, de Mendoza C, Joshi Y, et al. Impact of human immu-
nodeficiency virus type 1 (HIV-1) genetic diversity on performance of
four commercial viral load assays: LCx HIV RNA Quantitative, AM-
PLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and
NucliSens HIV-1 QT. J Clin Microbiol 2005; 43:3860–8.
29. Travers KU, Eisen GE, Marlink RG, et al. Protection from HIV-1 in-
fection by HIV-2. AIDS 1998; 12:224–5.
